Business
PRM,INmune Bio presenting biomarker discovery data
PRM,INmune Bio presenting biomarker discovery data.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4286R\n Proteome Sciences PLC\n 05 November 2021\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Reach announcement (non-regulatory)*\n \n \n \n \n \n \n \n 5 November 2021\n \n \n \n \n Proteome Sciences plc\n \n \n (\"Proteome Sciences\" or the \"Company\") \n \n \n \n \n \n Proteome Sciences and INmune Bio to present biomarker discovery data at Clinical Trials in Alzheimer's Disease 2021, Boston\n \n \n \n \n \n November 5th 2021 - London, UK & Boca Raton, USA - Proteome Sciences announces that Dr. Ian Pike, Chief Scientific Officer of Proteome Sciences, will be presenting data from a recent study performed with INmune Bio of Boca Raton, Florida, at the 2021 edition of Clinical Trials in Alzheimer's Disease conference being held in Boston, USA from November 7th to 9th. In this study, Proteome Sciences used its patented TMTcalibrator™ workflow to discover biomarkers supporting the response of Alzheimer's disease patients enrolled in a Phase I clinical study of INmune Bio's XPro1595.\n \n \n \n \n \n Xpro1595 is a novel sTNF antagonist targeting inflammation and related processes associated with Alzheimer's disease and other neurodegenerative conditions. A recently completed Phase I trial showed promising results, including evidence of reduced inflammation and re-myelination in brain white matter obtained through imaging studies. To further support decisions for future clinical studies, INmune Bio contracted Proteome Sciences to deliver an in-depth proteomics analysis of cerebrospinal fluid samples. \n \n \n \n \n \n This analysis discovered multiple peripheral biomarkers consistent with anti-inflammatory action, as well as pathways related to neurodegeneration, neuronal organization, synaptic function and myelination. Most strikingly, it revealed a broad reduction in the phosphorylation of tau protein, which is a common hallmark of Alzheimer's disease, and in particular at the pT217 site which has recently been reported as an important biomarker with strongly increased levels seen in advanced disease. Several of these proteins may be developed for monitoring progression in Phase II clinical studies.\n \n \n \n \n \n Dr. RJ Tesi, CEO, INmune Bio commented \"The use of biomarkers to drive clinical development forward in C...